A Phase 3, Randomized, Open-Label, Controlled, Multicenter Study of Zandelisib (ME- 401) in Combination With Rituximab Versus Standard Immunochemotherapy in Patients With Relapsed Indolent Non Hodgkin's Lymphoma (iNHL) - The COASTAL Study
Latest Information Update: 20 Oct 2025
At a glance
- Drugs Rituximab (Primary) ; Zandelisib (Primary) ; Bendamustine; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
- Indications Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms COASTAL
- Sponsors Lite Strategy
Most Recent Events
- 10 Sep 2025 According to MEI Pharma media release, MEI Pharma has changed its name to Lite Strategy.
- 05 May 2023 Status changed from active, no longer recruiting to discontinued.
- 13 Apr 2023 This trial has been discontinued in Hungary (End Date: 20 Mar 2023), according to European Clinical Trials Database record.